⌕
Cara Therapeutics · TVRD · Nasdaq
Tenet 47 · Mixed
Compare
$0.95−9.03%At closeTenet 47 · Mixed
$0.95−0.09 (−9.03%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Cara Therapeutics (TVRD) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 50% below its peak (through FY23), net margin −565.2%.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲38.0%
−18.2
FY21→FY25CAGR —
Free cash flow ($M)—
—
no FY25 valueCAGR —
Diluted EPS▲71.5%
−3.26
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+0.0%

7.8mn → 7.8mn diluted shares since FY25. Broadly flat, so EPS moves with net income rather than with the share count.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS−18.0R&D−8.7SG&A−26.7Op income8.5Tax & other−18.2Net income

Margin trend · direction beats level Gross Operating Net
1007550250%FY21FY25

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6151, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis. On the latest annual statement the reported earnings per share does not reconcile with net income to common shareholders divided by the reported share count (a factor of 1.393), so the two figures are on different bases. Both are shown as filed.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.020,968.041,867.023,028.0——
Cost of revenue
—0.00.06,174.07,266.00.0——
Gross profit
———14,794.034,601.023,028.0——
Research & development
18,878.018,011.023,650.0108,510.091,879.082,701.0▼23.8%−31.7%
Selling, general & admin
8,717.08,737.04,457.027,779.030,257.029,410.0▲96.0%−26.2%
Total operating expenses
27,595.026,748.028,107.0136,289.0122,136.0112,111.0▼4.8%−30.1%
Operating incomefeeds ROC rank
−27,595.0−26,748.0−28,107.0−121,495.0−87,535.0−89,083.0▲4.8%—
Other income, net
−6,224.01,375.0747.02,982.02,061.00.0——
Pretax income
−33,819.0−25,373.0−27,360.0−118,513.0−85,474.0−89,083.0▲7.3%—
Income tax
———0.00.0———
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−26,660.0−18,214.0−29,397.0−118,513.0−85,474.0−88,441.0▲38.0%—
Per share
Diluted EPSbuyback-sensitive
—−3.26−11.42−26.26−19.12−1.74▲71.5%—
Diluted shares (mn)
—7.782.574.514.4750.72▲202.3%−37.4%
Margins
Gross margin
———70.6%82.6%100.0%——
Operating margin
———−579.4%−209.1%−386.8%——
Net margin13th pct in Healthcare
———−565.2%−204.2%−384.1%——
† TTM = trailing four quarters through 2026-09-30.
FY12 – FY20 · 9 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 9 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-31 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.